Esperion Therapeutics (ESPR) Total Current Liabilities (2012 - 2026)

Esperion Therapeutics' Total Current Liabilities history runs 15 years deep, the most recent figure standing at $300.4 million for Q1 2026.

• Quarterly Total Current Liabilities rose 10.85% year-over-year to $300.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $300.4 million (up 10.85% YoY) and the FY2025 annual result came in at $300.8 million, up 22.16% from the prior year.
• Total Current Liabilities was $300.4 million for Q1 2026 at Esperion Therapeutics, roughly flat from $300.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $359.0 million in Q3 2025 and bottomed at $79.1 million in Q1 2022.
• A 5-year average of $183.2 million and a median of $164.5 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities slipped 19.21% — and 2025, when it soared 116.45%.
• Esperion Therapeutics' Total Current Liabilities stood at $92.3 million in 2022, then jumped by 69.24% to $156.2 million in 2023, then soared by 57.62% to $246.2 million in 2024, then advanced by 22.16% to $300.8 million in 2025, then slipped by 0.15% to $300.4 million in 2026.
• Business Quant data shows ESPR's Total Current Liabilities at $300.4 million in Q1 2026, $300.8 million in Q4 2025, and $359.0 million in Q3 2025.